With extensive knowledge in complex chemistry, Jane advises clients in life sciences, with a particular focus on small molecule pharmaceuticals. She has a deep understanding of the entire lifecycle of product development and aids her clients in protecting innovations from the initial discovery and testing through all later stage drug development, including protection for specific formulations and platform technologies. Through her extensive network of global contacts, she has strategically helped her clients build commercially valuable worldwide patent portfolios in over 50 countries and regions. Jane is also highly skilled in patent appeal and reexamination in front of the Patent Trial and Appeal Board. Beyond patent practice, she has extensive experience in IP due diligence connected to licensing and financing transactions, patent landscape, infringement and invalidity analyses, product clearance, and general IP strategy.
Jane advises and counsels a diverse range of clients from publicly traded companies, venture-funded start-ups, research institutions, to individual inventors. She has worked on numerous technologies, including a variety of pharmaceutical inventions for treatment of obesity, metabolic syndrome, cancers, idiopathic pulmonary fibrosis, bacterial infections, and liver diseases, as well as liposome delivery technologies. Outside of small molecule pharmaceuticals, Jane also manages portfolios involving next-generation sequencing applications, flowcells and microfluidic devices, polymer materials, medical devices, and aesthetics and personal care products. She also advises foreign internet and media clients on matters related to copyright protection, enforcement and data privacy.
Jane obtained her doctorate in organic chemistry at Pennsylvania State University, where her research concentrated on the design and synthesis of small molecule chiral ligands for transition metals catalyzed asymmetric reactions. Prior to joining Knobbe Martens, she worked as a patent agent in an IP boutique in New Jersey.
Jane joined the firm in 2011 and became a partner in 2018.
Jane 拥有深厚的络合物化学知识，可为生命科学领域客户提供有效建议，尤其侧重研究小分子药物。她对整个产品开发生命周期有着深刻的认识，致力于协助客户提供全程创新保护，全面覆盖从初始探索和测试到各后期药物开发阶段，包括保护特定配方和平台技术。从战略角度出发，依托广泛的全球联系网络，帮助客户在 50 多个国家和地区打造具有商业价值的全球专利组合。与此同时，Jane 十分善于处理呈交专利审判和上诉委员会的专利上诉和复审。除专利事务以外，还广泛涉猎许可和融资交易、专利地图、侵权和无效分析、产品清理和一般知识产权策略相关知识产权尽职调查。
Jane 为众多领域的客户提供咨询和建议，包括上市公司、风险投资初创公司、研究机构和个人发明家。协助保护包括治疗肥胖症、代谢综合征、癌症、特发性肺纤维化、细菌感染和肝病的多种药物发明在内的大量技术，以及脂质体递送技术。除小分子药物以外，Jane 还善于维护涉及新一代测序应用、流通池和微流体设备、聚合物材料、医疗器械及美学和个人护理产品的产品组合。同时，还面向国外互联网和媒体客户提供版权保护、执法和数据隐私相关建议。
Jane 拥有宾夕法尼亚州立大学有机化学博士学位，在校期间重点研究过渡金属催化不对称反应小分子手性配体设计和合成。加入 Knobbe Martens 之前，曾在新泽西州一家知识产权律所担任专利代理人。
Jane 于 2011 年加入公司并在 2018 年荣升为合伙人。
- 加州大学伯克利分校法学院（法学博士学位，2011 年），伯克利科技法律杂志
- 宾夕法尼亚州立大学（有机化学博士，2007 年）
- 中国科学技术大学（化学学士，2002 年）
Named among "Leaders in Law" by San Diego Business Journal (2023)
Named among Top 15 for Best Performing Attorneys in Biotech in Patexia's Patent Intelligence 2023 Report
Named a “Leading Litigator – IP Litigation, esp. Patent” in the 2023-2024 edition of Lawdragon’s “500 Leading Litigators in America” guide
- Named to the Best Lawyers: Ones to Watch guide, which “recognizes lawyers who are earlier in their careers for their outstanding professional excellence in private practice” for Patent Law (2022 - 2024)
Author, "How biotech and pharma firms can license IP from federal programs", The Pharma Letter (December 2022)
Contributor – Biotechnology Blog
Flavored E-cigarette Manufacturers Face Regulatory Challenges - Knobbe Martens (October 2023)
Shire v. Blackburn: Drawing the Line Between FDA Drug Labeling Regulations and State Law on Product Liability - Knobbe Martens (September 2023)
Supreme Court Issues Stay in Mifepristone Case, Preserving Status Quo for Now - Knobbe Martens (April 2023)
PTAB Adopts Phillips Standard for Claim Construction in AIA Proceedings - Knobbe Martens (October 2018)
FDA to Hold Public Hearing on Biosimilar Action Plan - Knobbe Martens (July 2018)
FDA Announces Public Meeting on Regulation of Cultured Meat Products - Knobbe Martens (June 2018)
China Drug Administration Proposes Pharmaceutical Data Protection Guidelines - Knobbe Martens (May 2018)
Supreme Court Will Not Review Pay-For-Delay Case over GSK's Lamictal - Knobbe Martens (November 2016)
Aralez's YOSPRALA Wins FDA Approval - Knobbe Martens (September 2016)
China applying for more patents than ever before as companies push to innovate, protect brand - South China Morning Post (June 2017)
Dai, Q.; Zhang, X. “Development of a New Class of C1-Symmetric Bisphosphine Ligands for Rhodium Catalyzed Asymmetric Hydrogenation.” Tetrahedron 2008, 64, 6943 - 6948.
Dai, Q.; Zhang, X. In Electronic Encyclopedia of Reagents for Organic Synthesis; John Wiley & Sons, 2008; published online.
Dai, Q.; Gao, W.; Liu, D.; Kapes, L. M.; Zhang, X. “Triazole-based monophosphine ligands for palladium catalyzed cross-coupling reactions of aryl chlorides.” J. Org. Chem. 2006, 71, 3928 – 3934.
Dai, Q.; Wang, C.; Zhang, X. “Chiral bisphospholane ligands (Me-Ketalphos): Synthesis of their Rh(I) complexes and applications in asymmetric hydrogenation.” Tetrahedron 2006, 62, 868 – 871.
Dai Q.; Yang, W.; Zhang, X. “Efficient rhodium catalyzed asymmetric hydrogenation for the synthesis of a new class of N-aryl β-amino acid derivatives.” Org. Lett. 2005, 7, 5343 – 5345.
Liu, D.; Gao, W.; Dai, Q.; Zhang, X. “Triazole-based monophosphines for Suzuki-Miyaura coupling and amination reactions of aryl chlorides.” Org. Lett. 2005, 7, 4907 – 4910.
Liu, D.; Dai, Q.; Zhang, X. “A new class of readily available and conformationally rigid phosphino-oxazoline ligands for asymmetric catalysis.” Tetrahedron 2005, 61, 6460 – 6471.
Dai, Q.; Yang, W.; Zhang, X. “Efficient synthesis of protected β-amino acid derivatives via asymmetric hydrogenation," The 230th ACS National Meeting, Washington, D.C., Fall 2005.
Dai, Q.; Liu, D.; Zhang, X. “Synthesis and application of new phosphine-oxazoline ligands,” The 228th ACS National Meeting, Philadelphia, Pennsylvania, Fall 2004.